Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

795
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
795
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

5.6K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
5.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

663
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
663
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

6.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
6.9K
Introduction to Hemostasis01:05

Introduction to Hemostasis

7.0K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
7.0K
Coagulation01:09

Coagulation

6.0K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preimplantation Genetic Testing for Families at Risk of Haemophilia: Ten-Year Single-Centre Experience.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

The Diagnosis and Evaluation of Women and Girls with Hemophilia and Hemophilia Carriers: Guidance from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Murine Models of Hemostasis: How to Assess Bleeding in Mice and Clinical Relevance of These Models for Testing New Therapeutics.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

Clinical and Laboratory Characterization of Acquired Von Willebrand Syndrome.

American journal of hematology·2026
Same author

Novel therapies for von Willebrand Disease.

Blood advances·2026
Same author

CX3CR1<sup>+</sup> synovial macrophages accumulate in the joint during experimental hemophilic arthropathy but are not required for acute synovitis.

Journal of thrombosis and haemostasis : JTH·2026

Related Experiment Video

Updated: Jun 19, 2025

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
08:30

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

11.2K

von Willebrand disease.

Omid Seidizadeh1, Jeroen C J Eikenboom2, Cécile V Denis3

  • 1Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.

Nature Reviews. Disease Primers
|July 25, 2024
PubMed
Summary
This summary is machine-generated.

Von Willebrand disease (VWD) is a common inherited bleeding disorder caused by von Willebrand factor defects. Accurate diagnosis and management are crucial due to complex symptoms and potential misdiagnosis.

More Related Videos

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow
11:42

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

11.6K
Pneumococcus Infection of Primary Human Endothelial Cells in Constant Flow
09:34

Pneumococcus Infection of Primary Human Endothelial Cells in Constant Flow

Published on: October 31, 2019

6.4K

Related Experiment Videos

Last Updated: Jun 19, 2025

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
08:30

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

11.2K
Live-cell Imaging of Platelet Degranulation and Secretion Under Flow
11:42

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

11.6K
Pneumococcus Infection of Primary Human Endothelial Cells in Constant Flow
09:34

Pneumococcus Infection of Primary Human Endothelial Cells in Constant Flow

Published on: October 31, 2019

6.4K

Area of Science:

  • Hematology
  • Genetics
  • Internal Medicine

Background:

  • Von Willebrand disease (VWD) is the most prevalent inherited bleeding disorder, characterized by excessive mucocutaneous bleeding.
  • VWD arises from quantitative or qualitative defects in the von Willebrand factor (VWF) glycoprotein, leading to various subtypes (Types 1, 2A, 2B, 2M, 2N, and 3).
  • Challenges in VWD diagnosis include symptom variability, external factors influencing VWF levels, and limited awareness among healthcare providers.

Purpose of the Study:

  • To provide a comprehensive overview of von Willebrand disease (VWD).
  • To highlight the complexities in diagnosing and managing this common inherited bleeding disorder.
  • To emphasize the importance of specialized diagnostic methods and therapeutic strategies.

Main Methods:

  • Review of VWD pathophysiology, classification, and clinical manifestations.
  • Discussion of diagnostic approaches, including phenotypic assays and genetic testing.
  • Overview of current management strategies, including desmopressin, VWF concentrates, and adjunctive therapies.

Main Results:

  • VWD presents with diverse bleeding symptoms, ranging from epistaxis and bruising to menorrhagia and surgical bleeding.
  • Quantitative VWF defects cause Type 1 and Type 3 VWD, while qualitative defects define Type 2 VWD.
  • Accurate diagnosis requires specialized testing due to VWD's complexity and influencing factors.

Conclusions:

  • Effective management of VWD involves VWF level augmentation (desmopressin or concentrates) and adjunctive treatments.
  • Addressing diagnostic challenges and improving disease awareness are critical for optimal patient care.
  • Continued research into VWF pathophysiology and treatment is essential for improving outcomes in patients with VWD.